公司专注于传染性疾病领域的创新药物研发及商业化，致力于为中国和全球患者提供可负担的高品质新型治疗方案。 The company focuses itself in the development and commercialization of innovative drugs for infectious diseases, and is committed to providing affordable and high-quality new treatment solutions for patients in China and around the world.
公司生物医药采取“3I”战略(创新Innovation、整合Integration和国际化Internationalization)，联合中科院武汉病毒所和中科院上海药物研究所新药研发优势，充分利用九州通已建立的商业化渠道优势，使越来越多的创新药惠及大众，推动我国药品创新与服务的高质量发展。 adopts the "3I" strategy (Innovation, Integration and Internationalization). By combining the strength of Wuhan Institute of Virology and Shanghai Institute of Materia Medica (Chinese Academy of Sciences) in new drug R&D, and by making full use of the well-established commercial channels from JoinTown Pharmaceutical Group, JKT BioPharma will be able to ensure accessibility of the public to more and more innovative drugs, and to bring drug innovation and services in China to a higher level.
400-607-8355 150-1069-6167
